NasdaqGS - Nasdaq Real Time Price USD

Alnylam Pharmaceuticals, Inc. (ALNY)

233.13

-6.88

(-2.87%)

As of 12:25:05 PM EDT. Market Open.

Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires?

We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands against other best growth stocks to buy according to billionaires. Can the Stock Market Have a Big Rebound? The stock market has been […]

Insider Monkey 22 hours ago

ALNY
-2.87%
High Growth Tech Stocks In US With Potential For Expansion

The United States market is currently experiencing a mixed performance with major indexes such as the Dow Jones and S&P 500 showing modest gains, while the tech-heavy Nasdaq Composite has seen slight declines amid fluctuating trade policies and tariff exemptions. In this dynamic environment, identifying high growth tech stocks with potential for expansion requires careful consideration of factors such as innovation, market adaptability, and resilience to external economic pressures.

Simply Wall St. 22 hours ago

ALNY
-2.87%
ASND

NTRA
How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

Political pressure and persistently high interest rates have some wondering if the industry’s model is broken.

The Wall Street Journal 4 days ago

ALNY
-2.87%
GILD

LLY
Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last?

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 5 days ago

ALNY
-2.87%
IMNM
Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy

President Trump’s newly announced tariff policy has done more than just push the stock markets deeper into correction territory — the sudden panic on Wall Street has increased worries about a full-blown recession hitting in the near future. According to USA Today, several big banks are putting the chance of a recession at 40% or higher. Only time will tell if we dip into recession. For now, worried investors are seeking ‘recession-proof’ stocks to shore up their portfolios. The biopharma team at

TipRanks 5 days ago

ALNY
-2.87%
AXSM
Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Long Term Growth Stock to Buy According to Billionaires?

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands against other best long term growth stocks to buy according to billionaires. As per Barclays, the US administration announced numerous executive […]

Insider Monkey 6 days ago

ALNY
-2.87%
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States

The FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without inhibitors.

Zacks 14 days ago

SNY

ALNY
-2.87%
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

CAMBRIDGE, Mass., April 01, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24th Annual Virtual Healthcare Conference on Tuesday, April 8, 2025 at 11:45 am ET.

Business Wire 14 days ago

ALNY
-2.87%
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Celebrates FDA Approval of Qfitlia Despite 5% Share Price Dip

Alnylam Pharmaceuticals (NasdaqGS:ALNY) saw a 13% share price increase in the last quarter, propelled by the FDA approval of Qfitlia™ for hemophilia A or B, a significant milestone reflecting its leadership in RNAi therapeutics. Despite broader market declines due to renewed tariff concerns impacting sectors like auto, Alnylam's R&D advancements and robust earnings report, showing nearly 35% growth in revenue, likely contributed to the stock's positive performance. The company's strategic...

Simply Wall St. 16 days ago

ALNY
-2.87%
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025

CAMBRIDGE, Mass., March 29, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark HELIOS-B Phase 3 clinical trial, which evaluated vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) in a population representative of today’s patients. Data were presented at the American College of Cardiology’s Annual Scientific Session (ACC.25) held in Chicago, Illinois. Th

Business Wire 16 days ago

ALNY
-2.87%
Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 18 days ago

SRPT
-1.06%
ALNY
-2.87%
Jazz (JAZZ) Down 9.2% Since Last Earnings Report: Can It Rebound?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 19 days ago

JAZZ

ALNY
-2.87%
^GSPC
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More

SAVA and ALNY are in the spotlight this week following a study failure and label expansion of lead drug, respectively.

Zacks 20 days ago

SAVAW

ALNY
-2.87%
OPTN
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks 22 days ago

ALNY
-2.87%
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Sees 17% Weekly Gain As Vutrisiran Faces FDA Decision

Alnylam Pharmaceuticals (NasdaqGS:ALNY) saw a 17% price increase over the past week, likely influenced by its recent announcements and market trends. The company's R&D progress showcase on February 25, featuring innovations like Nucresiran's high TTR knockdown capability and Vutrisiran's impending FDA decision, highlighted its strong pipeline, potentially boosting investor confidence. Additionally, the retirement announcement of co-founder Dr. Phillip A. Sharp on March 5 may have emphasized a...

Simply Wall St. 22 days ago

ALNY
-2.87%
Alnylam price target raised to $338 from $300 at Scotiabank

Scotiabank raised the firm’s price target on Alnylam (ALNY) to $338 from $300 and keeps an Outperform rating on the shares. The firm expects Amvuttra, the first transthyretin silencer to enter the market for the treatment of transthyretin amyloid cardiomyopathy, to see impressive uptake among the first-line setting given its unique mechanism of action, the analyst tells investors. The drug’s launch, however, will likely not gain momentum until 2H of 2025, the firm adds. Published first on TheFly

TipRanks 24 days ago

ALNY
-2.87%
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio

Alnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra.

Investor's Business Daily 24 days ago

BBIO

PFE

ALNY
-2.87%
Sector Update: Health Care Stocks Retreat Late Afternoon

Health care stocks fell late Friday afternoon, with the NYSE Health Care Index down 0.6% and the Hea

PREMIUM
MT Newswires 24 days ago

AZN

ALNY
-2.87%
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug

Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.

Pharmaceutical Technology 24 days ago

PFE

BBIO

ALNY
-2.87%
Alnylam Stock Jumps After the FDA Approves Its Heart Drug

Alnylam Pharmaceuticals shares rose 10% Friday after the company nabbed FDA approval to sell its drug Amvuttra to a larger population of patients with a genetic heart condition. The FDA cleared the drug after the close on Thursday, allowing Alnylam to compete against Pfizer and BridgeBio to treat patients with the disease. Alnylam has long been a favorite among biotech investors, but the company hasn’t yet shown it can transition from being a R&D innovator to a sustainable business.

The Wall Street Journal 24 days ago

ALNY
-2.87%
BBIO

PFE

Performance Overview

Return	ALNY	S&P 500 (^GSPC)
YTD	-0.93%	-7.64%
1-Year	+57.84%	+7.31%
3-Year	+39.32%	+23.66%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alnylam Pharmaceuticals, Inc. (ALNY)

Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires?

High Growth Tech Stocks In US With Potential For Expansion

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last?

Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy

Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Long Term Growth Stock to Buy According to Billionaires?

SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

Alnylam Pharmaceuticals (NasdaqGS:ALNY) Celebrates FDA Approval of Qfitlia Despite 5% Share Price Dip

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025

Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound?

Jazz (JAZZ) Down 9.2% Since Last Earnings Report: Can It Rebound?

Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More

Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?

Alnylam Pharmaceuticals (NasdaqGS:ALNY) Sees 17% Weekly Gain As Vutrisiran Faces FDA Decision

Alnylam price target raised to $338 from $300 at Scotiabank

Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio

Sector Update: Health Care Stocks Retreat Late Afternoon

Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug

Alnylam Stock Jumps After the FDA Approves Its Heart Drug

Performance Overview